These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18300126)

  • 1. Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients.
    Ucmak H; Kokoglu OF; Hosoglu S; Dogan E; Sayarlioglu H; Kuzhan N; Isik IO
    Ren Fail; 2008; 30(2):227-32. PubMed ID: 18300126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
    Kokoglu OF; Uçmak H; Hosoglu S; Cetinkaya A; Kantarceken B; Buyukbese MA; Isik IO
    J Gastroenterol Hepatol; 2006 Mar; 21(3):575-80. PubMed ID: 16638102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.
    Covic A; Maftei ID; Mardare NG; Ioniţă-Radu F; Totolici C; Tuţă L; Golea O; Covic M; Volovăţ C; Gusbeth-Tatomir P; Mircescu G
    J Nephrol; 2006; 19(6):794-801. PubMed ID: 17173254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
    Ayaz C; Celen MK; Yuce UN; Geyik MF
    World J Gastroenterol; 2008 Jan; 14(2):255-9. PubMed ID: 18186564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Pegylated Interferon Alpha-2b Monotherapy in Hepatitis C Virus-Infected Children with End-Stage Renal Disease on Hemodialysis.
    Mogahed EA; Abdelaziz H; Helmy H; Ghita H; Abdel Mawla MA; Hassanin F; Fadel FI; El-Karaksy H
    J Interferon Cytokine Res; 2016 Dec; 36(12):681-688. PubMed ID: 27656950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.
    Köse Ş; Senger SS; Ersan G; Çavdar G
    Clin Exp Nephrol; 2013 Feb; 17(1):115-9. PubMed ID: 22814955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection.
    Wang KL; Xing HQ; Zhao H; Liu JW; Gao DL; Zhang XH; Yao HY; Yan L; Zhao J
    World J Gastroenterol; 2014 Apr; 20(14):4071-5. PubMed ID: 24744598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C.
    Liu CH; Liang CC; Liu CJ; Lin JW; Chen SI; Hung PH; Tsai HB; Lai MY; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2010 Sep; 51(5):541-9. PubMed ID: 20645865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C?
    Potthoff A; Wiegand J; Lüth JB; Wedemeyer H; Manns MP; Tillmann HL
    Clin Nephrol; 2005 Mar; 63(3):232-5. PubMed ID: 15786827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.
    Sikole A; Dzekova P; Selja N; Gaseva M; Nikolov IG; Zabzun M; Muharemi S; Asani A; Amitov V; Mena S; Grunevska V; Ivanovski L; Polenakovic M
    Ren Fail; 2007; 29(8):961-6. PubMed ID: 18067041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease.
    Peck-Radosavljevic M; Boletis J; Besisik F; Ferraz ML; Alric L; Samuel D; Messinger D; Tietz A; Cheinquer H
    Clin Gastroenterol Hepatol; 2011 Mar; 9(3):242-8. PubMed ID: 21056689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of chronic hepatitis C virus infection in hemodialysis patients].
    Kaya S
    Mikrobiyol Bul; 2008 Jul; 42(3):525-34. PubMed ID: 18822900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis.
    Casanovas-Taltavull T; Baliellas C; Llobet M; Cruzado JM; Castellote J; Casanova A; Niubó J; Valls C; Serrano T
    Transplant Proc; 2007 Sep; 39(7):2125-7. PubMed ID: 17889113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation.
    Casanovas-Taltavull T; Baliellas C; Benasco C; Serrano TT; Casanova A; Pérez JL; Guerrero L; González MT; Andres E; Gil-Vernet S; Casais LA
    Am J Gastroenterol; 2001 Apr; 96(4):1170-7. PubMed ID: 11316166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.
    Rendina M; Schena A; Castellaneta NM; Losito F; Amoruso AC; Stallone G; Schena FP; Di Leo A; Francavilla A
    J Hepatol; 2007 May; 46(5):768-74. PubMed ID: 17383045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.